• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Servier acquires Pixuvri from CTI BioPharma

    PHARMA TIMES

    Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone)

    BUSINESSWIRE

    Servier acquire non-Hodgkin B-cell lymphoma treatment PIXUVRI® from CTI BioPharm

    BUSINESSWIRE

    PIXUVRI® (pixantrone) Receives +ve CHMP Opinion to Convert Conditional Approval

    BUSINESSWIRE

    CTI, Servier’s Pixuvri fails in post-marketing trial

    PHARMA TIMES

    CTI Biopharma Says Phase III Trial Evaluating Pixuvri With Rituximab In Comparison To Gemcitabine Combined With Rituximab Did Not Meet Its Primary Endpoint

    REUTERS

    CTI’s Pixuvri fails a pivotal Ph3 study-can it remain on the market?

    ENDPTS

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.